AKER - Akers Biosciences Jumps On COVID-19 Vaccine Progress Will Remain Volatile
Source: marketbeat
In March, the obscure biotech company Akers Biosciences (AKER) became known to a larger number of investors on the news it had entered into a licensing deal with Premas Biotech to work together on developing a vaccine to treat COVID-19, including Akers' expertise in navigating and accelerating the complex regulatory process.
At the time, the share price of the company predictably jumped on the news, as traders quickly entered and exited positions in the company. The firm recently soared much more on news of its advancement in the next stage of the development